Key Takeaways
- Hims & Hers (HIMS) stock gained 7% following the announcement of a broadened collaboration with Eli Lilly
- Healthcare providers using the platform can now prescribe Zepbound vials, KwikPen, and Foundayo through LillyDirect fulfillment
- This expansion follows a comparable agreement with Novo Nordisk in March for Wegovy distribution
- Leerink Partners analyst Michael Cherny raised concerns about Hims’ value proposition as a simple access point to pharmaceutical products
- CEO Andrew Dudum defended the strategy by drawing parallels to Netflix’s evolution as a platform
Shares of Hims & Hers Health (HIMS) jumped 7% on Thursday following the company’s announcement of an enhanced collaboration that enables healthcare providers to prescribe Eli Lilly’s weight management drugs directly through its telehealth platform.
Hims & Hers Health, Inc., HIMS
Healthcare providers utilizing the Hims platform now have the capability to route prescriptions for Zepbound vials, KwikPen devices, and Foundayo directly to LillyDirect’s pharmacy network. This arrangement provides customers with self-pay pricing options while connecting them to licensed medical professionals who can prescribe FDA-approved GLP-1 treatments.
The partnership positions Hims to offer what the company describes as a comprehensive selection of FDA-approved GLP-1 medications through its digital health platform. The service package includes clinical oversight and nutritional counseling delivered through a subscription-based framework.
This marks the second significant GLP-1 collaboration for Hims in just two months. Last month, the company reached an agreement with Novo Nordisk that resolved a patent infringement dispute, with Hims agreeing to distribute branded Ozempic and Wegovy through its platform.
The Novo agreement required concessions from Hims. The telehealth company scaled back its large-volume compounding operations for GLP-1 drugs as part of the settlement. The newly announced Lilly partnership appears to follow a similar framework.
Hims established a solid market position throughout 2024’s GLP-1 supply shortage, when surging demand and constrained production from pharmaceutical giants created opportunities for the telehealth provider. With supply constraints now easing, market conditions have transformed.
Analyst Questions Platform Value Proposition
Michael Cherny, an analyst at Leerink Partners, provided a cautious assessment of the announcement. While acknowledging that Hims is broadening its service offerings and “serving as an intermediary to create more options” for consumers, Cherny questioned the depth of value being provided.
He noted it remains “hard to tell what role Hims is playing here beyond being the front door to patients accessing Lilly products.” This concern grows more relevant as the company transitions away from its compounding operations.
CEO Defends Strategy with Netflix Analogy
CEO Andrew Dudum rejected suggestions that these partnerships signal a strategic pullback. In his statement, he drew comparisons between Hims and Netflix during its formative years.
“Netflix wasn’t just renting DVDs,” Dudum stated. “It was changing consumer behavior by ruthlessly prioritizing choice and inventing new pathways to the things people wanted the most.”
The company highlighted its weight management membership program as proof of a differentiated offering. Subscribers receive round-the-clock access to medical care teams, customized nutritional guidance, continuous clinical monitoring, and community support through the Hims & Hers Weight Loss network.
According to Hims, the platform’s objective is to align users with appropriate treatment options tailored to their specific medical backgrounds, personal preferences, and wellness objectives.
Market participants appeared receptive to the CEO’s positioning. HIMS stock maintained a 0.4% gain later in trading while the S&P 500 declined modestly. Eli Lilly shares remained unchanged.
The Eli Lilly collaboration represents Hims’ continued evolution in the GLP-1 marketplace, transitioning from a provider of compounded medications to a distribution platform for branded pharmaceutical products.
